Research Article

Urotensin-II gene rs228648 polymorphism associated with the risk of diabetes mellitus

Yawei Zhao¹,* , Shuhua Fang¹,²,* , Kerong Que¹,* , Guangli Xu¹, Heng Zhang¹, Cong Qi¹ and Nian Yang¹

¹Department of Pharmacy, Jurong Hospital affiliated to Jiangsu University, Jurong 212400, Jiangsu, China; ²Zhenjiang First People’s Hospital, Zhenjiang 212000, Jiangsu, China

Correspondence: Nian Yang (NianYang_9@163.com)

Background: Urotensin-II (UII) rs228648 polymorphism has been reported to be associated with the risk of diabetes mellitus (DM) with inconsistent results. The present study sought to reassess the relationship between this polymorphism and susceptibility to DM by meta-analysis.

Methods: Relevant eligible studies and whole genome association study (GWAS) data electronically searched were pooled to evaluate the strength of the association with odds ratios (ORs) and 95% confidence intervals (CIs).

Results: Seven case–control studies involving 894 cases and 1186 controls were finally included in the meta-analysis. Overall analyses indicated that UII gene rs228648 variant was significantly associated with reduced risk of DM (allele, A vs. G: OR = 0.68, 95%CI = 0.56–0.82; dominant, AA+GA vs. GG: OR = 0.70, 95%CI = 0.53–0.91; homozygote, AA vs. GG: OR = 0.41, 95%CI = 0.28–0.61; recessive, AA vs. GA+GG: OR = 0.36, 95%CI = 0.19–0.71). In subgroup analyses based on ethnicity, the results showed a significant association of rs228648 polymorphism with decreased risk of DM in Chinese population under all five genetic models as well as in non-Chinese population under heterozygote and recessive models. Stratified analyses by specific type of DM also presented a significant association for common diabetes mellitus (CDM) under allele and homozygote as well as gestational diabetes mellitus (GDM) under all genetic models except for homozygote model. However, the synthetic analysis with GWAS data suggested an increased risk of DM with rs228648 effect allele in European population (OR = 1.01, 95%CI = 1.00–1.02).

Conclusion: The present meta-analysis preliminarily suggested a potentially opposite role of rs228648 polymorphism associated with DM risk in the Chinese and European population. Further studies are in great request to verify the results.

Introduction

Diabetes mellitus (DM) posting one of the most common chronic diseases develops generally in individuals with insulin resistance in insulin target tissues and impaired insulin secretion from pancreatic β-cells in the presence of appropriate genetic and environmental factors [1,2]. Recently, a growing body of evidence proposes that a neurohormonal peptide named Urotensin-II (UII) may be implicated in the pathogenesis of DM [3].

UII initially isolated from the urophysis of teleost fish is a somatostatin-like cyclic undecapeptide and known as the most potent mammalian vasoconstrictor specified as yet [4,5], exerting its biological effects through interaction with its specific receptor that a member of a G-protein–coupled receptor superfamily, originally termed GPR14 [6–8]. It has been documented that one of the regions localized to 1p36-p32 in the UII gene showed potential linkage with type 2 diabetes (T2D) [9,10]. Elevated plasma levels of UII and increased UII expression have been also evidenced in patients with DM and in numerous diabetic tissues in previous studies [11–13]. Furthermore, it was reported that UII could reduce insulin secretion in response to glucose and arginine in the perfused rat pancreas, thereby, potentially contributing to a
defective insulin secretion and/or aggravated insulin resistance in DM [14,15]. However, the underlying mechanism in details remains not elucidated yet.

Considering the potential influence of genetic alteration on the expression or activity of corresponding genes which may result in altered risk of diseases, a number of studies have investigated the role of polymorphic variations in UII gene in the susceptibility to DM to date. Expectedly, a previously identified single nucleotide polymorphism 143G>A (Thr21Met, rs228648) mapped on the exon 1 of UII gene has been reportedly linked to DM [16], however, results from relevant association studies are inconsistent. For instance, Okumus et al. [16] and Zhu et al. [17] found a significant association of UII rs228648 variant with a decreased risk of DM in the Turkish and Chinese populations, respectively, but Suzuki et al. [18] failed to show such association in the Japanese population. The discrepancy among previous studies may be due to the limited sample size or ethnicity variation. Therefore, to derive a more precise estimation, we performed a meta-analysis of available relevant studies to systematically reassess the association between UII gene rs228648 polymorphism and susceptibility to DM. Moreover, with regard to the potential counterpart in clinical characteristics and genetic context involved in the pathogenesis of DM [19–21], the studies conducted with the gestational diabetes mellitus (GDM) patients were also enrolled for the synthesis analysis regarding this association.

**Methods**

**Literature search strategies**

Potential eligible studies evaluating the association between UII gene rs228648 polymorphism and susceptibility to DM were electronically searched in Pubmed, Embase, Cochrane Library, Wanfang, China National Knowledge Infrastructure, and the Chinese Biomedicine Databases up to July 2018 using the following limits: Humans, and article in English or Chinese. We developed a search strategy using the following query in various combinations: ['Urotensin II' or 'Urotensin-II' or 'UII' or 'U-II'] and ['SNP' or 'variant' or 'polymorphisms' or 'polymorphism']. Additionally, all the relevant references of the identified studies were further reviewed for additional eligible studies. If necessary, we contacted authors for additional data. In case of duplication, only the study with large sample size and complete information was selected.

**Selection criteria and data extraction**

Studies would be considered eligible if they met the following criteria: (1) Studies assessing the association of UII gene rs228648 polymorphism with the risk of DM, including GDM. (2) Studies with case–control design. (3) Studies containing available genotype frequency in cases and controls. (4) Studies providing sufficient information to estimate an odds ratio (OR) with 95% confidence interval (CI). The major reasons for exclusion were as follows: (1) Studies reporting duplicate data. (2) Studies without control design. (3) Studies lack of sufficient data to extract the genotype frequency or estimate the concerned ORs and 95%CIs. Information extracted from each individual study was collected by two independent reviewers using a uniform tabulation and any discrepancy was resolved by discussion or a consultation with a third reviewer to reach a consensus. The information was extracted as follows: first author, year of publication, country, ethnicity, types of DM, distribution of genotype or allele in cases and controls, source of control, genotype method, and evidence of Hardy–Weinberg equilibrium (HWE).

**Synthetic analysis of whole genome association study**

Considering the limited sample size and population representation of the original case–control study, the additional synthetic analysis with whole genome association study (GWAS) study was also performed. GWAS data were retrieved with the T2D Knowledge Portal database (http://www.type2diabetesgenetics.org/). The ORs with 95%CIs of individual studies were extracted and synthesized to evaluate the association of rs228648 polymorphism effect allele with DM risk by Stata 12.0 software (Stata Corp., College Station, U.S.A.).

**Statistical analysis**

Individual or pooled ORs with 95% CIs were calculated to assess the strength of associations between the UII gene rs228648 polymorphism and the risk of DM using Review Manager version 5.2 software (provided by the Cochrane Collaboration, Oxford, U.K.; http://www.cochrane.org/software/revman.htm). The significance of the pooled OR was determined by the Z-test and P<0.05 was considered significant [22]. The pooled analyses were performed with an appropriate effect model according to the between-study heterogeneity detected by the Cochran’s Q-test and the I²-test (P<0.10 and I² > 50% indicated evidence of heterogeneity) [23]. In the presence of substantial between-study heterogeneity, the random effect model was used for the synthesis analysis; otherwise the fixed effect model was selected [24,25]. Sensitivity analysis was carried out by sequential omission of individual studies to check the stability of the pooled findings.
of the results. Additionally, the potential publication bias was estimated by Begg's funnel plot and Egger's regression test by Stata 12.0 software (Stata Corp., College Station, U.S.A.) and $P > 0.05$ indicated no evidence of publication bias [26,27].

### Result

#### Study characteristics

The flow chart summarizing study selection is shown in Figure 1. Totally, 53 potentially relevant studies were initially identified according to the search strategy. Applying the study selection criteria, seven case–control studies involving 894 cases and 1186 controls were finally included in the meta-analysis [16–18,28–31]. Of which, there were five studies conducted in Chinese population, and two studies conducted in Japanese and Turkish population, respectively, which were categorized as 'non-Chinese' population. In the included studies, five studies were examined for common DM (CDM) and two studies focused on GDM. Five studies were reported in Chinese and two were reported in English. The genotype frequencies of controls in each included study were in agreement with HWE. Detailed characteristics of selected studies are presented in Table 1.

#### Meta-analysis results

As shown in Figure 2 and Table 2, the overall results showed a significant association of rs228648 variant with reduced risk of DM under the allele genetic model when all the seven studies were pooled into the meta-analysis ($A$ vs. $G$: OR $= 0.68$, 95%CI $= 0.56–0.82$). Since only the allele frequency was provided in the studies by Sun et al. [28] and Suzuki et al. [18], only other five studies were included in the pooled analyses under other four genetic models. Similarly,
Table 1 Characteristics of the included studies in the meta-analysis

| First author | Year | Country | Ethnicity | Type  | Genotype case | Genotype control | Source of control | Genotype method | HWE test |
|--------------|------|---------|-----------|-------|---------------|------------------|------------------|----------------|---------|
| Suzuki*      | 2004 | Japan   | Japanese  | CDM   | AA/GA/GG      | AA/GA/GG         | Population       | PCR-RFLP       | Y       |
| Sun*         | 2002 | China   | Chinese   | CDM   | 113/297       | 111/205          | Population       | SBE            | Y       |
| Zhou         | 2015 | China   | Chinese   | CDM   | 15/63/42      | 28/50/22         | Hospital         | PCR-RFLP       | Y       |
| Li           | 2011 | China   | Chinese   | CDM   | 10/29/42      | 28/141/131       | Hospital         | PCR-LDR        | Y       |
| Tan          | 2006 | China   | Chinese   | GDM   | 8/25/37       | 18/23/29         | Hospital         | PCR-RFLP       | Y       |
| Zhu          | 2002 | China   | Chinese   | CDM   | 17/91/58      | 28/64/29         | Hospital         | PCR-RFLP       | Y       |
| Okumus       | 2012 | Turkey  | Turkish   | CDM   | 10/99/4       | 127/138/26       | Population       | PCR-RFLP       | Y       |

Abbreviations: CDM, common diabetes mellitus; GDM, gestational diabetes mellitus; HWE, Hardy–Weinberg equilibrium. Y, in agreement with HWE. *Only the allele distribution in cases and controls were provided in the two studies (A/G).

Figure 2. Forest plot for UII gene rs228648 polymorphism and DM risk under allele genetic model (A vs. G)

A significant association was observed between this variant and DM (dominant model, AA+GA vs. GG: OR = 0.70, 95%CI = 0.53–0.91; homozygote model, AA vs. GG: OR = 0.41, 95%CI = 0.28–0.61; recessive model, AA vs. GA+GG: OR = 0.36, 95%CI = 0.19–0.71).

In the subgroup analyses based on ethnicity, we also found a significant association in Chinese population (dominant model, AA+GA vs. GG: OR = 0.61, 95%CI = 0.46–0.81; allele model, A vs. G: OR = 0.65, 95%CI = 0.56–0.77; homozygote model, AA vs. GG: OR = 0.40, 95%CI = 0.27–0.61; heterozygote model, GA vs. AA: OR = 0.70, 95%CI = 0.52–0.94; recessive model, AA vs. GA+GG: OR = 0.48, 95%CI = 0.33–0.69) as well as in non-Chinese population (heterozygote model, GA vs. AA: OR = 4.66, 95%CI = 1.58–13.78; recessive model, AA vs. GA+GG: OR = 0.13, 95%CI = 0.06–0.25), however only one single study for the non-Chinese population was included. The stratified analyses by specific type of DM indicated a significant association of rs228648 polymorphism with decreased risk of CDM (allele model, A vs. G: OR = 0.72, 95%CI = 0.57–0.91; homozygote model, AA vs. GG: OR = 0.50, 95%CI = 0.30–0.82). Likewise, such association was also observed for GDM (dominant model, AA+GA vs. GG: OR = 0.58, 95%CI = 0.37–0.91; allele model, A vs. G: OR = 0.56, 95%CI = 0.42–0.76; homozygote model, AA vs. GG: OR = 0.31, 95%CI = 0.17–0.57; recessive model, AA vs. GA+GG: OR = 0.37, 95%CI = 0.21–0.64).

Publication bias and sensitivity analysis

As shown in Figure 3, the Begg’s funnel plot for publication bias test showed no obvious asymmetry, indicating no evidence of publication bias, which was further supported by the Egger’s test (A vs. G: P = 0.958 > 0.05). For the sensitivity analyses by sequential omission of individual studies, no substantial alteration for the pooled ORs was observed under the allele, homozygote and recessive models; however, the significance of pooled ORs was excessively affected by excluding the study by Zhu et al. [17] and Zhou et al. [29] under dominant model and excluding the study by Okumus et al. [16] under heterozygote model. Nevertheless, most results of the sensitivity analyses still revealed a significant association, suggesting the reliability and robustness of the meta-analysis.
### Table 2 Meta-analysis results of the association between UII gene rs228648 polymorphism and DM risk

| Contrasts               | Number of studies | OR [95%CI]          | P    | Heterogeneity | Effect model |
|-------------------------|-------------------|---------------------|------|---------------|--------------|
|                         |                   |                     | P_H  | I^2            |              |
| AA+GA vs. GG            | 5                 | 0.70 [0.53, 0.91]   | 0.007| 0.12          | 45%          | F            |
| Chinese                 | 4                 | 0.61 [0.46, 0.81]   | 0.0006| 0.91         | 0%           | F            |
| Non-Chinese             | 1                 | 2.67 [0.91, 7.84]   | 0.07 | -             | -            | -            |
| CDM                     | 3                 | 0.87 [0.45, 1.68]   | 0.67 | 0.04          | 69%          | R            |
| GDM                     | 2                 | 0.58 [0.37, 0.91]   | 0.02 | 0.59          | 0%           | F            |
| A vs. G                 | 7                 | 0.68 [0.56, 0.82]   | <0.001| 0.07         | 48%          | R            |
| Chinese                 | 5                 | 0.65 [0.56, 0.77]   | <0.001| 0.65         | 0%           | F            |
| Non-Chinese             | 2                 | 0.76 [0.38, 1.51]   | 0.43 | 0.004         | 88%          | R            |
| CDM                     | 5                 | 0.72 [0.57, 0.91]   | 0.006| 0.05          | 58%          | R            |
| GDM                     | 2                 | 0.56 [0.42, 0.76]   | 0.0002| 0.97         | 0%           | F            |
| AA vs. GG               | 5                 | 0.41 [0.28, 0.61]   | <0.001| 0.31         | 16%          | F            |
| Chinese                 | 4                 | 0.40 [0.27, 0.61]   | <0.001| 0.2          | 35%          | F            |
| Non-Chinese             | 1                 | 0.51 [0.15, 1.76]   | 0.29 | -             | -            | -            |
| CDM                     | 3                 | 0.50 [0.30, 0.82]   | 0.006| 0.2           | 39%          | F            |
| GDM                     | 2                 | 0.31 [0.17, 0.57]   | 0.0002| 0.74         | 0%           | F            |
| GA vs. GG               | 5                 | 0.90 [0.54, 1.51]   | 0.7  | 0.02          | 65%          | R            |
| Chinese                 | 4                 | 0.70 [0.52, 0.94]   | 0.02 | 0.94          | 0%           | F            |
| Non-Chinese             | 1                 | 4.66 [1.58, 13.78]  | 0.005| -             | -            | -            |
| CDM                     | 3                 | 1.13 [0.45, 2.83]   | 0.8  | 0.004         | 82%          | R            |
| GDM                     | 2                 | 0.73 [0.45, 1.19]   | 0.21 | 0.61          | 0%           | F            |
| AA vs. GA+GG            | 5                 | 0.36 [0.19, 0.71]   | 0.003| 0.002         | 76%          | R            |
| Chinese                 | 4                 | 0.48 [0.33, 0.69]   | <0.001| 0.16         | 42%          | F            |
| Non-Chinese             | 1                 | 0.13 [0.06, 0.25]   | <0.001| -            | -            | -            |
| CDM                     | 3                 | 0.38 [0.11, 1.15]   | 0.09 | <0.001        | 88%          | R            |
| GDM                     | 2                 | 0.37 [0.21, 0.64]   | 0.0004| 0.98         | 0%           | F            |

Values in bold indicate a significant association. Abbreviations: CDM, common diabetes mellitus; GDM, gestational diabetes mellitus; OR, odd ratio; 95%CI, 95% confidence interval; F, fixed model; R, random model; P_H, P-value for the heterogeneity test.

---

**Figure 3.** Funnel plot for UII gene rs228648 polymorphism and DM risk under allele genetic model (A vs. G)
Figure 4. Forest plot for the effect allele of rs228648 and DM risk with GWAS data (A vs. G)

**Synthetic analysis of GWAS studies**

As shown in Figure 4, a total of 13 GWAS studies were retrieved after excluding the GoT2D GWAS dataset which was duplicated from the GoT2D GWAS+replication dataset with a larger sample size. All the GWAS studies were mainly conducted in European population. As a result, the synthetic analysis with a fixed effect model showed a significant association of rs228648 polymorphism effect allele with increased DM risk (OR = 1.01, 95%CI = 1.00–1.02).

**Discussion**

The study is the first to reliably quantify the association between UII gene rs228648 polymorphism and susceptibility to DM. Our meta-analysis implied a potentially opposite role of rs228648 polymorphism in different populations, suggesting that the UII rs228648 variant seemed to be associated with a reduced risk of DM in the Chinese population while an increased risk in European population.

Over decades, numerous polymorphic regions in UII gene encoding for UII peptide, including rs228648 polymorphism, have been identified and correlated to many diseases, such as DM, diabetic retinopathy [16], breast cancer [32], Behcet’s disease [33], and systemic sclerosis [34]. Notably, Yumrutas et al. [32] found that Thr21Met (143G>A, rs228648) polymorphism in the UII gene was associated with the risk of developing breast cancer and the variant genotype was significantly associated with reduced plasma expression of UII, proposing a possible mechanism for UII involvement in the altered risks of diseases. Furthermore, Zhou et al. [29] found that the variant AA genotype was associated with a decreased risk of DM and impaired insulin resistance in patients with GDM. Additionally, the study by Ong et al. [35] revealed that the GGT haplotype (−605G, 143G, and 3836T) was associated with higher plasma level of U-II, insulin and higher homeostasis model assessment of insulin resistance index and β-cell function, suggesting the possible role of UII 143G>A (rs228648) polymorphism in the glycemic control via the regulation of plasma UII levels and insulin resistance. Although relevant studies have prompted a potential genetic association...
of UII gene rs228648 polymorphism with DM, the results seem to be inconsistent; the underlying mechanism for the association of this polymorphism with DM remains largely unknown as well.

Overall, the present meta-analysis involving 894 cases and 1186 controls from seven case–control studies suggested a significant effect of UII gene rs228648 variant on the decreased risk of DM. In the subgroup analysis based on ethnicity, we found a significant association between UII gene rs228648 polymorphism and reduced risk of DM in Chinese population under all five genetic models with relatively less heterogeneity but only under heterozygote and recessive models, suggesting that this association may be comparatively evident in Chinese population. However, only few studies were included in the analysis regarding non-Chinese population, more necessity is required for validation of this association in other populations. In addition, the stratification analysis by specific types of DM indicated an association of UII gene rs228648 polymorphism with CDM as well as GDM, suggesting a possibility that the UII gene rs228648 polymorphism may causally and partially contribute to the pathogenesis of CDM and GDM on the basis of similar hereditary context [20,21]. However, this association was potentially evident in GDM due to more significant associations suggested by more models with less between-study heterogeneity in the present study. Whereas, these findings should be interpreted with cautions because the studies concerning the association between the variant and DM are all conducted in Chinese population and with limited sample size. Conversely, a significant association of rs228648 effect allele with increased DM risk was indicated in European population, suggesting the potential importance of ethnicity difference concerning the association. Additionally, the gene–gene or gene–environment interaction, and the relation between marker and causal variants may also contribute to the difference. Nevertheless, several concerns should also be noted for the GWAS studies conducted in European population in consideration of only approximately 1% increase in DM risk for the effect allele, the lack of detailed data on genotype distribution in cases and controls, and the potential population stratification. Accordingly, more studies with well design are still needed to verify our results and explore the underlying mechanism.

Despite an appropriate approach applied for the present study, some limitations should be acknowledged yet. First, most of the included individual studies were retrieved from Chinese population, however, the rs228648 polymorphism is most predominant in the South Asian and European populations compared with East Asians. No population from South Asian, American, and fewer population from other East Asian countries were represented in the present study, thus our results may be primarily applicable to limited populations. Second, limited studies conducted in the Chinese population were enrolled in the meta-analysis in spite of no evident publication bias indicated, which would limit our confidence in drawing conclusions especially in the subgroup analysis regarding the specific forms of DM and ethnicity. Third, our estimates were based on unadjusted data, some important compounding factors such as BMI, gender, age, etc., were not taken into consideration due to the lack of original information. Fourth, as DM is multifactor-affected disease, potential environment–gene, gene–gene interactions including haplotype effects may be of importance for the observed disease-effect unconformity [16], but we had insufficient data to perform an evaluation of such interactions.

Conclusion
In conclusion, the present meta-analysis suggested that UII gene rs228648 polymorphism may be associated with a decreased risk of DM in Chinese population but an increased risk in European population. In light of the limitations existed, additional larger studies allowing stratification analyses for environment–gene interaction, haplotype effects, type and ethnicity specifications are greatly suggested to further clarify the possible role of the concerned genetic variant in the etiology of DM in future work.

Author Contribution
N.Y. conceived and designed the study; Y.Z. and K.Q. analyzed the data; G.X., H.Z., and C.Q. created all tables and figures; S.F. drafted the manuscript; N.Y. made critical revision of the manuscript. All authors read and approved the final manuscript.

Funding
The authors declare that there are no sources of funding to be acknowledged.

Competing Interests
The authors declare that there are no competing interests associated with the manuscript.
Abbreviations
CDM, common diabetes mellitus; CI, confidence interval; DM, diabetes mellitus; GDM, gestational diabetes mellitus; GWAS, whole genome association study; HWE, Hardy–Weinberg equilibrium; OR, odds ratio; T2D, type 2 diabetes; UII, Urotensin-II.

References
1 DeFronzo, R.A., Bonadonna, R.C. and Ferrannini, E. (1992) Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15, 318–368, https://doi.org/10.2337/diacare.15.3.318
2 Liu, Y., Chen, S., Jing, Z., Hou, X., Chen, Y., Song, X. et al. (2015) Association of LEPR Gin223Arg polymorphism with T2DM: a meta-analysis. Diabetes Res. Clin. Pract. 109, e21–e26, https://doi.org/10.1016/j.diabres.2015.05.042
3 Xie, N. and Liu, L. (2009) Elevated expression of utrotensin II and its receptor in great artery of type 2 diabetes and its significance. Biomed. Pharmacother. 63, 734–741, https://doi.org/10.1016/j.biopharm.2009.04.036
4 Douglas, S.A. and Ohlstein, E.H. (2000) Human utrotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc. Med. 10, 229–237, https://doi.org/10.1016/S1050-1738(00)00069-4
5 Zhang, Y., Li, Y., Wei, R., Wang, Z., Bu, D., Zhao, J. et al. (2008) Urotensin II is an autocrine/paracrine growth factor for aortic adventitia of rat. Regul. Pept. 151, 88–94, https://doi.org/10.1016/j.regpep.2008.10.004
6 Ames, R.S, Sarau, H.M., Chambers, J.K., Willette, R.N., Aiyar, N.V., Romanic, A.M. et al. (1999) Human utrotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401, 282–286, https://doi.org/10.1038/45809
7 Mori, M., Sugo, T., Abe, M., Shimomura, Y., Kurihara, M., Kitada, C. et al. (1999) Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). Biochem. Biophys. Res. Commun. 265, 123–129, https://doi.org/10.1006/bbrc.1999.1640
8 Liu, O., Pong, S., Zeng, Z., Zhang, Q., Howard, A.D., Williams, D.J. et al. (1999) Identification of utrotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem. Biophys. Res. Commun. 266, 174–178, https://doi.org/10.1006/bbrc.1999.1796
9 Mori, Y., Otabe, S., Dina, C., Yasuda, K., Populaire, C., Lececeur, C. et al. (2002) Genome-wide search for type 2 diabetes in Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate Loci on 7p and 11p. Diabete 51, 1247–1255, https://doi.org/10.2337/diabetes.51.4.1247
10 Wenyi, Z., Suzuki, S., Hirai, M., Hinokio, Y., Tanizawa, Y., Matsutani, A. et al. (2003) Role of utrotensin II gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects. Diabetologia 46, 972–976, https://doi.org/10.1007/s00125-003-1145-1
11 Totsune, K., Takahashi, K., Arihara, Z., Sone, M., Murakami, O., Ito, S. et al. (2004) Elevated plasma levels of immunoreactive utrotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 25, 1809–1814, https://doi.org/10.1016/j.peptides.2004.06.024
12 Totsune, K., Takahashi, K., Arihara, Z., Sone, M., Ito, S. and Murakami, O. (2003) Increased plasma utrotensin II levels in patients with diabetes mellitus. Clin. Sci. (Lond.) 104, 1–5, https://doi.org/10.1042/cs1040001
13 Ong, K.L., Wong, L.Y. and Cheung, B.M. (2008) The role of utrotensin II in the metabolic syndrome. Peptides 29, 859–867, https://doi.org/10.1016/j.peptides.2007.06.003
14 Silvestre, R.A., Egido, E.M., Hernandez, R., Leprince, J., Chatenet, D., Tollemer, H. et al. (2004) Urotensin-II is present in pancreatic extracts and inhibits insulin release by the perfused rat pancreas. Eur. J. Endocrinol. 151, 803–809, https://doi.org/10.1530/ej.0.1510803
15 Silvestre, R.A., Rodriguez-Gallardo, J., Egido, E.M. and Marco, J. (2001) Inhibition of insulin release by utrotensin II—a study on the perfused rat pancreas. Horm. Metab. Res. 33, 379–381, https://doi.org/10.1055/s-2001-15414
16 Okumus, S., Igci, Y.Z., Taskin, T., Oztuzu, S., Güler, B., Eslif, Z. et al. (2012) Association between Thr21Met and Ser89Asn polymorphisms of the utrotensin-II (UTS2) gene, diabetes mellitus, and diabetic retinopathy. Curr. Eye Res. 37, 921–929, https://doi.org/10.3109/0271106X.2012.688181
17 Zhu, F., Ji, L. and Luo, B. (2002) The role of utrotensin II gene in the genetic susceptibility to type 2 diabetes in Chinese populations. Zhonghua Yi Xue Za Zhi 82, 1473–1475
18 Suzuki, S., Wenyi, Z., Hirai, M., Hinokio, Y., Suzuki, C., Yamada, T. et al. (2004) Genetic variations at utrotensin II and utrotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese. Peptides 25, 1803–1808, https://doi.org/10.1016/j.peptides.2004.03.030
19 Karagöz, H., Erden, A., Ozer, O., Esmeray, K., Cetinkaya, A., Avci, D. et al. (2015) The role of blood groups in the development of diabetes mellitus after gestational diabetes mellitus. Acta Diabetol. 53, 433–437, https://doi.org/10.1007/s00592-015-0814-0
20 Kohler, M., Ziegler, A.G. and Beyerlein, A. (2016) Development of a simple tool to predict the risk of postpartum diabetes in women with gestational diabetes mellitus. Ther. Clin. Risk Manag. 11, 1613–1417
21 Retnakaran, R. and Shah, B.R. (2016) Sex of the baby and future maternal risk of Type 2 diabetes in women who had gestational diabetes. Diabet. Med. 33, 956–960, https://doi.org/10.1111/dme.12989
22 Wan, G., Cao, Y., Li, W., Li, Y. and Li, F. (2014) The catechol-O-methyltransferase Val158Met polymorphism contributes to the risk of breast cancer in the Chinese population: an updated meta-analysis. J. Breast Cancer 17, 149–156, https://doi.org/10.4048/jbc.2014.7.2.149
23 Higgins, J.P., Thompson, S.G., Deeks, J.J. and Altman, D.G. (2003) Measuring inconsistency in meta-analyses. BMJ 327, 557–560, https://doi.org/10.1136/bmj.327.7414.557
24 Mantel, N. and Haenszel, W. (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J. Nati. Cancer Inst. 22, 719–748
25 DerSimonian, R. and Laird, N. (1986) Meta-analysis in clinical trials. Control. Clin. Trials 7, 177–188, https://doi.org/10.1016/0197-2456(86)90046-2
26 Begg, C.B. and Mazumdar, M. (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088–1101, https://doi.org/10.2307/2533446
27 Egger, M., Davey, S.G., Schneider, M and Minder, C. (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629–634, https://doi.org/10.1136/bmj.315.7109.629
28 Sun, H., Du, W., Zuo, J., Wu, G., Shi, G., Shen, Y. et al. (2002) The association of two single nucleotide polymorphisms in PRKCZ and UTS2 respectively with type 2 diabetes in Han people of northern China. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao* **24**, 223–227
29 Zhou, P., Gao, X., Xiao, H. and He, Y. (2015) Association analysis between SNP rs228648 in urotensin-2 gene and gestational diabetes mellitus. *Chin. J. Diabetes* **23**, 486–488
30 Li, H. (2011) *Association of Genetic Variation of UTS2 Gene with Type 2 Diabetes Mellitus AND Hypertension*, The Tenth National Endocrinology Congress of the Chinese Medical Association, Suzhou, China, http://www.china-endo.org/2011/cn/
31 Tan, Y., Fan, Z. and Yang, H. (2006) Role of urotensin II gene in the genetic susceptibility to gestational diabetes mellitus in northern Chinese women. *Zhonghua Fu Chan Ke Za Zhi* **41**, 732–735
32 Yumrutas, O., Oztuzcu, S., Buyukhatipoglu, H., Bozgeyik, I., Bozgeyik, E., Igci, Y.Z. et al. (2015) The role of the UTS2 gene polymorphisms and plasma Urotensin-II levels in breast cancer. *Tumour Biol.* **36**, 4427–4432, https://doi.org/10.1007/s13277-015-3082-2
33 Oztuzcu, S., Ulasli, M., Pehlivan, Y., Cevik, M.O., Cengiz, B., Gogebakan, B. et al. (2013) Thr21Met (T21M) but not Ser89Asn (S89N) polymorphisms of the urotensin-II (UTS-II) gene are associated with Behcet’s disease (BD). *Peptides* **42**, 97–100, https://doi.org/10.1016/j.peptides.2012.12.013
34 Pehlivan, Y., Gogebakan, B., Oztuzcu, S., Ozgen, M., Cetin, G.Y., Bayraktar, R. et al. (2012) Association between Thr21Met and Ser89Asn polymorphisms of the urotensin II gene and systemic sclerosis. *J. Rheumatol.* **39**, 106–111, https://doi.org/10.3899/jrheum.110509
35 Ong, K.L., Wong, L.Y., Man, Y.B., Leung, R.Y., Song, Y., Lam, K.S. et al. (2006) Haplotypes in the urotensin II gene and urotensin II receptor gene are associated with insulin resistance and impaired glucose tolerance. *Peptides* **27**, 1659–1667, https://doi.org/10.1016/j.peptides.2006.02.008